Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Montage of Rare Disease Day contributors: Baroness Nicola Blackwood (Chair Genomics England), Bina Shah (Founder Project 8p), Emily Crossley (CEO, Duchenne UK), Rose and Zeryk Hacking (rare disease family), Gary Lineker OBE (OHCC Ambassador) and Prof. Chas Bountra.
Rare Disease Day contributors: Baroness Nicola Blackwood (Chair Genomics England), Bina Shah (Founder Project 8p), Emily Crossley (CEO, Duchenne UK), Rose and Zeryk Hacking (rare disease family), Gary Lineker OBE (OHCC Ambassador) and Prof. Chas Bountra.

Rare Diseases affect 350 million people worldwide. There are over 7,000 known rare diseases and only 5% have an approved treatment, presenting a major global challenge.

Rare Disease Day is an annual international event raising awareness of rare diseases and their impact on the lives of millions. This year, Oxford hosted a webinar as part of the global virtual event series.  The Oxford-Harrington Rare Disease Centre (OHC), a partnership with the Harrington Discovery Institute in the University’s Department of Paediatrics, brings together Oxford’s significant rare disease expertise across departments.

The OHC hosted a guest lecture by the University’s Pro-Vice Chancellor for Innovation, Prof. Chas Bountra, entitled: Lesson from 2020: Together we can do the impossible, for Rare Disease Day. Highlighting the importance of collaboration, Prof. Bountra talked about how 2020 showed that, with the alignment of stakeholders and resources, what would have taken decades to achieve in the past can now be achieved in months. Years of research and infrastructure development in the University provide the foundations of an effective and rapid response to emerging challenges, whether the COVID pandemic or the global unmet need for rare disease treatments. The Department of Paediatrics hosts Oxford’s COVID-19 vaccine trials, where trials in children have now started.

Baroness Nicola Blackwood offered a message of support. From her own diagnostic journey and with her perspective as Chair of Genomics England, she shared her hope that expansion of genomic sequencing in patients and collaboration with the OHC will deliver much-needed treatments for multiple rare diseases.

Insights from rare disease patients and carers included Gary Lineker OBE, an OHC Ambassador, whose two-month-old son was diagnosed with, and subsequently cured of, a rare blood cancer.

Follow @OHRareDisease to keep up to date with news from The Oxford-Harrington Rare Disease Centre.

Similar stories

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.

New research reveals relationship between particular brain circuits and different aspects of mental wellbeing

Researchers at the University of Oxford have uncovered previously unknown details about how changes in the brain contribute to changes in wellbeing.

Night-time blood pressure assessment is found to be important in diagnosing hypertension

Around 15% of people aged 40-75 may have a form of undiagnosed high blood pressure (hypertension) that occurs only at night-time. Because they do not know about this, and therefore are not being treated for it, they are at a higher risk of cardiovascular disease such as stroke, heart failure, and even death, suggests new research from the University of Oxford published in the British Journal of General Practice.

Major new NIHR Global Health Research Unit to focus on data science and genomic surveillance of antimicrobial resistance

The Centre for Genomic Pathogen Surveillance, part of the Big Data Institute at the University of Oxford, has been awarded funding worth £7m for their work as an NIHR Global Health Research Unit (GHRU) for the next five years. The Centre’s research and capacity building work focuses on delivering genomics and enabling data for the surveillance of antimicrobial resistance (AMR).